• Clinicians demonstrated up to 100% adherence to EndoPredict test results in extended endocrine therapy decision making

As a leader in genetic testing and precision medicine, we are pleased to announce new data from the prospective EXET trial involving EndoPredict Breast Cancer Prognostic Test, our prognostic and predictive test for ER positive, HER2 negative early-stage breast cancer.

Presented in an abstract at the recent 2022 ASCO Annual Meeting, lead author Adam Brufsky and colleagues showed that EndoPredict was a significant predictor of clinical decisions, even after adjusting for clinical factors, when it came to extended endocrine therapy (EET) for ER positive, HER2 negative early-stage breast cancer patients.¹

Study title: Adherence to EndoPredict test scores for extended endocrine therapy management in prospective Extended Endocrine Trial (EXET)

Current guidelines advise that individuals with ER positive breast cancer undergo five years of endocrine therapy with consideration of up to 10 years of EET. The relative benefit of EET beyond five years is minimal for most women, but patients at high risk of late recurrence may benefit. EndoPredict is a second generation gene expression test which clearly distinguishes patients at high or low risk of breast cancer recurrence with its EPclin Risk Score, and it’s also the only test validated to provide recurrence risk data for 5-15 years.²

The EXET study included 411 patients with an average age of 62 years (27 – 90). 107 received adjuvant chemotherapy (26%) and 71 were lymph node positive (17.3%). To evaluate the impact on decision making for EET, chart review was performed one year after EndoPredict test results were clinically disclosed.

EndoPredict test results were adhered to very closely in EET decision making, with 100% adherence rate for EPclin high-risk patients across all subgroups (with/without chemotherapy, node negative and node positive). Comparably, the rate of EET was significantly different for those with EPclin low-risk scores (EPclin Score ≤ 3.3) (OR 8.5×10^-4 [95% CI 6.8×10^-6, 6.0×10^-3], p-value 5.7×10^-68).

EndoPredict EPclin Risk Score was a significant predictor of clinical decisions on EET, even after adjusting for clinical variables such as nodal status, tumor grade and stage, age at diagnosis, and adjuvant chemotherapy status.

Gene expression testing is helping more clinicians and their breast cancer patients make the right long-term treatment decisions, and providing additional peace-of-mind for patient safety.

Learn more about how EndoPredict is guiding long-term treatment decisions.

About Myriad Genetics

We are a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling doctors to better detect, treat and prevent disease.

Myriad discovers and provides genetic and genomic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and provide access to the right treatments.

References

1. Brufsky, Adam et al. “Adherence To Endopredict Test Scores For Extended Endocrine Therapy Management In The Prospective Endopredict Extended Endocrine Trial (EXET).“. Journal Of Clinical Oncology, vol 40, no. 16_suppl, 2022, pp. 537-537
2. Filipits, Dubsky et al. “Prediction Of Distant Recurrence Using EndoPredict Among Women With ER+, HER2− Node-Positive And Node-Negative Breast Cancer Treated With Endocrine Therapy Only“. Clinical Cancer Research, vol 25, no. 13, 2019, pp. 3865-3872